{"schema_version":"secwatch.filing_event.v1","accession":"0001551152-24-000002","form_type":"8-K","ticker":"ABBV","cik":"0001551152","company_name":"AbbVie Inc.","filed_at":"2024-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.573709+00:00","generated_at":"2026-06-07T03:05:34.299975+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"AbbVie updates Q4 and FY 2023 adjusted EPS guidance for $282M IPR&D expense","bullets":["Q4 2023 acquired IPR&D and milestones expense of $282M pre-tax reduces GAAP and adjusted EPS by $0.15.","Updated Q4 2023 adjusted diluted EPS guidance range: $2.72 - $2.76 (prior $2.87 - $2.91).","Full-year 2023 adjusted diluted EPS guidance now $11.04 - $11.08 (prior $11.19 - $11.23).","Full-year 2023 acquired IPR&D and milestones expense totals $778M.","AbbVie notes these expenses are inherently unforecastable; final Q4 results may differ."],"urls":{"canonical":"https://secwatch.observer/filing/0001551152-24-000002","json":"https://secwatch.observer/filing/0001551152-24-000002.json","markdown":"https://secwatch.observer/filing/0001551152-24-000002.md","text":"https://secwatch.observer/filing/0001551152-24-000002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1551152/000155115224000002/0001551152-24-000002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1551152/000155115224000002/abbv-20240105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T03:05:34.299975+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4097eb16e36e9a3c185713fb515720a7432bb40e","claim":"AbbVie Inc. reported full-year ended December 31, 2023 results: EPS $11.04 - $11.08. Guidance reaffirmed.","evidence_excerpt":"AbbVie’s full-year 2023 adjusted diluted earnings per share guidance range, including the impact of fourth quarter 2023 acquired IPR&D and milestones expense, is $11.04 - $11.08.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115224000002/0001551152-24-000002-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full-year ended December 31, 2023"},{"label":"EPS","value":"$11.04 - $11.08"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"cf7c21116e8eb62869df375417a0ee1b30a2b630","claim":"AbbVie Inc. reported quarter ended December 31, 2023 results: EPS $2.72 - $2.76. Guidance reaffirmed.","evidence_excerpt":"AbbVie’s fourth quarter 2023 adjusted diluted earnings per share guidance range, including the impact of fourth quarter 2023 acquired IPR&D and milestones expense, is $2.72 - $2.76.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115224000002/0001551152-24-000002-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended December 31, 2023"},{"label":"EPS","value":"$2.72 - $2.76"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}